- Home
- Publications
- Publication Search
- Publication Details
Title
Circulating tumor cells
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 15, Issue 5, Pages 496-503
Publisher
Informa UK Limited
Online
2014-02-13
DOI
10.4161/cbt.28020
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer heterogeneity: implications for targeted therapeutics
- (2013) R Fisher et al. BRITISH JOURNAL OF CANCER
- Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs
- (2013) Francesco Fabbri et al. CANCER LETTERS
- Promising biomarkers for predicting the outcomes of patients withKRASwild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis
- (2013) Zu-Yao Yang et al. INTERNATIONAL JOURNAL OF CANCER
- KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
- (2013) Emanuele Valtorta et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer Cell Phenotypes, in Fifty Shades of Grey
- (2013) A. Marusyk et al. SCIENCE
- Role of targeted agents in metastatic colorectal cancer
- (2013) Hans Prenen et al. Targeted Oncology
- Cellular Heterogeneity and Molecular Evolution in Cancer
- (2012) Vanessa Almendro et al. Annual Review of Pathology-Mechanisms of Disease
- Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
- (2012) Leonie JM Mekenkamp et al. BMC CANCER
- Intratumor Heterogeneity: Evolution through Space and Time
- (2012) C. Swanton CANCER RESEARCH
- Heterogeneity of Epidermal Growth Factor Receptor Status and Mutations of KRAS/PIK3CA in Circulating Tumor Cells of Patients with Colorectal Cancer
- (2012) C. Gasch et al. CLINICAL CHEMISTRY
- Circulating Tumor Cells: Liquid Biopsy of Cancer
- (2012) C. Alix-Panabieres et al. CLINICAL CHEMISTRY
- KRASandBRAFmutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue
- (2012) Bianca Mostert et al. INTERNATIONAL JOURNAL OF CANCER
- Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
- (2012) J. Sastre et al. ONCOLOGIST
- EMT Inducers Catalyze Malignant Transformation of Mammary Epithelial Cells and Drive Tumorigenesis towards Claudin-Low Tumors in Transgenic Mice
- (2012) Anne-Pierre Morel et al. PLoS Genetics
- Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero
- (2011) P. Gazzaniga et al. ANNALS OF ONCOLOGY
- KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
- (2011) N Knijn et al. BRITISH JOURNAL OF CANCER
- Disseminated and circulating tumor cells in gastrointestinal oncology
- (2011) F.C. Bidard et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- Review of biomarkers in colorectal cancer
- (2010) K. F. Newton et al. Colorectal Disease
- Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells
- (2010) Michal Mego et al. INTERNATIONAL JOURNAL OF CANCER
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Relevance of KRAS in Human Cancers
- (2010) Sylwia Jančík et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Hypoxia Activates the K-Ras Proto-Oncogene to Stimulate Angiogenesis and Inhibit Apoptosis in Colon Cancer Cells
- (2010) Min Zeng et al. PLoS One
- Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents
- (2009) J. Tol et al. ANNALS OF ONCOLOGY
- Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
- (2009) S. J. Cohen et al. ANNALS OF ONCOLOGY
- Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer
- (2009) L.-C. Yen et al. CLINICAL CANCER RESEARCH
- Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
- (2009) Nicola Normanno et al. Nature Reviews Clinical Oncology
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
- (2009) Andrea Sartore-Bianchi et al. PLoS One
- Transforming growth factor-β signaling in epithelial-mesenchymal transition and progression of cancer
- (2009) Kohei MIYAZONO PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer
- (2009) M. Craig Miller et al. Journal of Oncology
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
- (2008) Steven J. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer
- (2008) Silke Lankiewicz et al. Molecular Oncology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started